"What" Series

What's clinical adverse event and it's classification?

17 January 2024
2 min read

Clinical adverse events (AEs) are defined as any unfavorable or unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of a medical product, whether related to or not related to such product.

AEs can be classified by severity into five categories:

1) Mild AEs: No intervention is required; no discomfort; no incapacity; no inconvenience; no hospitalization.

2) Moderate AEs: Intervention needed for recovery/relief; some limitation on daily activities; some incapacity; some inconvenience; possible hospitalization.

3) Severe AEs: Inpatient treatment; life-threatening; prolonged or permanent incapacity; prolonged or permanent incapacity; hospitalization for observation.

4) Life-threatening AEs: Events that result in death.

5) Death: AEs related death.

EU Sanctions KRAZATI (adagrasib) as a Selective Therapy for Advanced NSCLC Sufferers Exhibiting KRAS G12C Alteration
Latest Hotspot
3 min read
EU Sanctions KRAZATI (adagrasib) as a Selective Therapy for Advanced NSCLC Sufferers Exhibiting KRAS G12C Alteration
16 January 2024
Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).
Read →
Exploring the Latest TSLP monoclonal antibody Deal by Aiolos Bio: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest TSLP monoclonal antibody Deal by Aiolos Bio: A Guide to Rapidly Accessing Transaction Insights
16 January 2024
GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.
Read →
Xeris Biopharma Secures Global Exclusive Rights to Distribute Xeriject® Version of Teprotumumab
Latest Hotspot
3 min read
Xeris Biopharma Secures Global Exclusive Rights to Distribute Xeriject® Version of Teprotumumab
16 January 2024
Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.
Read →
What is IUPAC?
"What" Series
2 min read
What is IUPAC?
16 January 2024
The International Union of Pure and Applied Chemistry (IUPAC) is a non-governmental organization dedicated to promoting chemistry-related activities.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.